Table 2.

Comparison of the exposures achieved with cefepime and taniborbactam in humans and in mice

	%fT>CT								fAUC0–24 (mg·h/L)
Cefepime
CT  (mg/L)	4	8	16	32	64	128	256	512
humana	100	84	58	35	11	0	0	0
mouse HSRb	96	83	59	38	8	0	0	0
Taniborbactam
CT  (mg/L)	0.25	0.5	1	2	4	8	16	32
humanc	100	100	100	100	80	51	17	0	229
moused 24:1	85	56	23	3	0	0	0	0	17.0
moused 12:1	99	85	56	23	3	0	0	0	33.9
moused 6:1	100	99	85	56	23	3	0	0	67.8
moused 4:1	100	100	88	64	33	8	0	0	101
moused 3:1	100	100	99	85	56	23	3	0	136
moused,e  2:1	100	100	100	100	84	53	16	0	204

^aHuman exposures for a dose of 2 g q8h as a 2 h infusion estimated based on best-fit pharmacokinetic parameters of cefepime in healthy subjects from Phase I studies upon co-administration of taniborbactam.

^bMouse exposure estimated based on best-fit pharmacokinetic parameters of cefepime in infected mice.

^cHuman exposures for a dose of 0.5 g q8h as a 2 h infusion estimated based on best-fit pharmacokinetic parameters of taniborbactam in healthy subjects from Phase I studies.¹⁰

^dMouse exposure estimated based on best-fit pharmacokinetic parameters of taniborbactam in infected mice. Ratios represent the proportions of cefepime:taniborbactam, relative to the doses of the cefepime HSR.

^eMouse exposure was comparable to that achieved in humans and is denoted in bold.